Report Detail

Pharma & Healthcare Global and United States Anaplastic Lymphoma Kinase ALK Inhibitor Market Insights, Forecast to 2027

  • RnM4342144
  • |
  • 03 September, 2021
  • |
  • Global
  • |
  • Pages: NA
  • |
  • QYResearch
  • |
  • Pharma & Healthcare

Table of Contents

    1 Study Coverage

    • 1.1 Anaplastic Lymphoma Kinase ALK Inhibitor Product Introduction
    • 1.2 Market by Type
      • 1.2.1 Global Anaplastic Lymphoma Kinase ALK Inhibitor Market Size Growth Rate by Type
      • 1.2.2 First Generation ALK Inhibitor
      • 1.2.3 Second Generation ALK Inhibitor
      • 1.2.4 Third Generation ALK Inhibitor
    • 1.3 Market by Application
      • 1.3.1 Global Anaplastic Lymphoma Kinase ALK Inhibitor Market Size Growth Rate by Application
      • 1.3.2 Hospital Pharmacy
      • 1.3.3 Retail Pharmacy
      • 1.3.4 Others
    • 1.4 Study Objectives
    • 1.5 Years Considered

    2 Executive Summary

    • 2.1 Global Anaplastic Lymphoma Kinase ALK Inhibitor Market Size, Estimates and Forecasts
      • 2.1.1 Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue 2016-2027
      • 2.1.2 Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales 2016-2027
    • 2.2 Global Anaplastic Lymphoma Kinase ALK Inhibitor, Market Size by Region: 2016 VS 2021 VS 2027
    • 2.3 Anaplastic Lymphoma Kinase ALK Inhibitor Historical Market Size by Region (2016-2021)
      • 2.3.1 Global Anaplastic Lymphoma Kinase ALK Inhibitor Retrospective Market Scenario in Sales by Region: 2016-2021
      • 2.3.2 Global Anaplastic Lymphoma Kinase ALK Inhibitor Retrospective Market Scenario in Revenue by Region: 2016-2021
    • 2.4 Anaplastic Lymphoma Kinase ALK Inhibitor Market Estimates and Projections by Region (2022-2027)
      • 2.4.1 Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales Forecast by Region (2022-2027)
      • 2.4.2 Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Forecast by Region (2022-2027)

    3 Global Anaplastic Lymphoma Kinase ALK Inhibitor Competitor Landscape by Players

    • 3.1 Global Top Anaplastic Lymphoma Kinase ALK Inhibitor Manufacturers by Sales
      • 3.1.1 Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Manufacturer (2016-2021)
      • 3.1.2 Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share by Manufacturer (2016-2021)
    • 3.2 Global Top Anaplastic Lymphoma Kinase ALK Inhibitor Manufacturers by Revenue
      • 3.2.1 Key Anaplastic Lymphoma Kinase ALK Inhibitor Manufacturers Covered: Ranking by Revenue
      • 3.2.2 Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Manufacturers (2016-2021)
      • 3.2.3 Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Share by Manufacturers (2016-2021)
      • 3.2.4 Global Anaplastic Lymphoma Kinase ALK Inhibitor Market Concentration Ratio (CR5 and HHI) (2016-2021)
      • 3.2.5 Global Top 10 and Top 5 Companies by Anaplastic Lymphoma Kinase ALK Inhibitor Revenue in 2020
      • 3.2.6 Global Anaplastic Lymphoma Kinase ALK Inhibitor Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    • 3.3 Global Anaplastic Lymphoma Kinase ALK Inhibitor Price by Manufacturers
    • 3.4 Global Anaplastic Lymphoma Kinase ALK Inhibitor Manufacturing Base Distribution, Product Types
      • 3.4.1 Anaplastic Lymphoma Kinase ALK Inhibitor Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Anaplastic Lymphoma Kinase ALK Inhibitor Product Type
      • 3.4.3 Date of International Manufacturers Enter into Anaplastic Lymphoma Kinase ALK Inhibitor Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type (2016-2027)

    • 4.1 Global Anaplastic Lymphoma Kinase ALK Inhibitor Market Size by Type (2016-2021)
      • 4.1.1 Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Type (2016-2021)
      • 4.1.2 Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Type (2016-2021)
      • 4.1.3 Anaplastic Lymphoma Kinase ALK Inhibitor Average Selling Price (ASP) by Type (2016-2021)
    • 4.2 Global Anaplastic Lymphoma Kinase ALK Inhibitor Market Size Forecast by Type (2022-2027)
      • 4.2.1 Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales Forecast by Type (2022-2027)
      • 4.2.2 Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Forecast by Type (2022-2027)
      • 4.2.3 Anaplastic Lymphoma Kinase ALK Inhibitor Average Selling Price (ASP) Forecast by Type (2022-2027)

    5 Breakdown Data by Application (2016-2027)

    • 5.1 Global Anaplastic Lymphoma Kinase ALK Inhibitor Market Size by Application (2016-2021)
      • 5.1.1 Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Application (2016-2021)
      • 5.1.2 Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Application (2016-2021)
      • 5.1.3 Anaplastic Lymphoma Kinase ALK Inhibitor Price by Application (2016-2021)
    • 5.2 Anaplastic Lymphoma Kinase ALK Inhibitor Market Size Forecast by Application (2022-2027)
      • 5.2.1 Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales Forecast by Application (2022-2027)
      • 5.2.2 Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Forecast by Application (2022-2027)
      • 5.2.3 Global Anaplastic Lymphoma Kinase ALK Inhibitor Price Forecast by Application (2022-2027)

    6 United States by Players, Type and Application

    • 6.1 United States Anaplastic Lymphoma Kinase ALK Inhibitor Market Size YoY Growth 2016-2027
      • 6.1.1 United States Anaplastic Lymphoma Kinase ALK Inhibitor Sales YoY Growth 2016-2027
      • 6.1.2 United States Anaplastic Lymphoma Kinase ALK Inhibitor Revenue YoY Growth 2016-2027
      • 6.1.3 United States Anaplastic Lymphoma Kinase ALK Inhibitor Market Share in Global Market 2016-2027
    • 6.2 United States Anaplastic Lymphoma Kinase ALK Inhibitor Market Size by Players (International and Local Players)
      • 6.2.1 United States Top Anaplastic Lymphoma Kinase ALK Inhibitor Players by Sales (2016-2021)
      • 6.2.2 United States Top Anaplastic Lymphoma Kinase ALK Inhibitor Players by Revenue (2016-2021)
    • 6.3 United States Anaplastic Lymphoma Kinase ALK Inhibitor Historic Market Review by Type (2016-2021)
      • 6.3.1 United States Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share by Type (2016-2021)
      • 6.3.2 United States Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Market Share by Type (2016-2021)
      • 6.3.3 United States Anaplastic Lymphoma Kinase ALK Inhibitor Price by Type (2016-2021)
    • 6.4 United States Anaplastic Lymphoma Kinase ALK Inhibitor Market Estimates and Forecasts by Type (2022-2027)
      • 6.4.1 United States Anaplastic Lymphoma Kinase ALK Inhibitor Sales Forecast by Type (2022-2027)
      • 6.4.2 United States Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Forecast by Type (2022-2027)
      • 6.4.3 United States Anaplastic Lymphoma Kinase ALK Inhibitor Price Forecast by Type (2022-2027)
    • 6.5 United States Anaplastic Lymphoma Kinase ALK Inhibitor Historic Market Review by Application (2016-2021)
      • 6.5.1 United States Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share by Application (2016-2021)
      • 6.5.2 United States Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Market Share by Application (2016-2021)
      • 6.5.3 United States Anaplastic Lymphoma Kinase ALK Inhibitor Price by Application (2016-2021)
    • 6.6 United States Anaplastic Lymphoma Kinase ALK Inhibitor Market Estimates and Forecasts by Application (2022-2027)
      • 6.6.1 United States Anaplastic Lymphoma Kinase ALK Inhibitor Sales Forecast by Application (2022-2027)
      • 6.6.2 United States Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Forecast by Application (2022-2027)
      • 6.6.3 United States Anaplastic Lymphoma Kinase ALK Inhibitor Price Forecast by Application (2022-2027)

    7 North America

    • 7.1 North America Anaplastic Lymphoma Kinase ALK Inhibitor Market Size YoY Growth 2016-2027
    • 7.2 North America Anaplastic Lymphoma Kinase ALK Inhibitor Market Facts & Figures by Country
      • 7.2.1 North America Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Country (2016-2021)
      • 7.2.2 North America Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Country (2016-2021)
      • 7.2.3 United States
      • 7.2.4 Canada

    8 Asia Pacific

    • 8.1 Asia Pacific Anaplastic Lymphoma Kinase ALK Inhibitor Market Size YoY Growth 2016-2027
    • 8.2 Asia Pacific Anaplastic Lymphoma Kinase ALK Inhibitor Market Facts & Figures by Region
      • 8.2.1 Asia Pacific Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Region (2016-2021)
      • 8.2.2 Asia Pacific Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Region (2016-2021)
      • 8.2.3 China
      • 8.2.4 Japan
      • 8.2.5 South Korea
      • 8.2.6 India
      • 8.2.7 Australia
      • 8.2.8 Australia
      • 8.2.9 Indonesia
      • 8.2.10 Thailand
      • 8.2.11 Malaysia

    9 Europe

    • 9.1 Europe Anaplastic Lymphoma Kinase ALK Inhibitor Market Size YoY Growth 2016-2027
    • 9.2 Europe Anaplastic Lymphoma Kinase ALK Inhibitor Market Facts & Figures by Country
      • 9.2.1 Europe Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Country (2016-2021)
      • 9.2.2 Europe Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Country (2016-2021)
      • 9.2.3 Germany
      • 9.2.4 France
      • 9.2.5 U.K.
      • 9.2.6 Italy

    10 Latin America

    • 10.1 Latin America Anaplastic Lymphoma Kinase ALK Inhibitor Market Size YoY Growth 2016-2027
    • 10.2 Latin America Anaplastic Lymphoma Kinase ALK Inhibitor Market Facts & Figures by Country
      • 10.2.1 Latin America Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Country (2016-2021)
      • 10.2.2 Latin America Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Country (2016-2021)
      • 10.2.3 Mexico
      • 10.2.4 Brazil
      • 10.2.5 Argentina
      • 10.2.6 Colombia

    11 Middle East and Africa

    • 11.1 Middle East and Africa Anaplastic Lymphoma Kinase ALK Inhibitor Market Size YoY Growth 2016-2027
    • 11.2 Middle East and Africa Anaplastic Lymphoma Kinase ALK Inhibitor Market Facts & Figures by Country
      • 11.2.1 Middle East and Africa Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Country (2016-2021)
      • 11.2.2 Middle East and Africa Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Country (2016-2021)
      • 11.2.3 Turkey
      • 11.2.4 Saudi Arabia
      • 11.2.5 UAE

    12 Company Profiles

    • 12.1 Astellas Pharma
      • 12.1.1 Astellas Pharma Corporation Information
      • 12.1.2 Astellas Pharma Description and Business Overview
      • 12.1.3 Astellas Pharma Anaplastic Lymphoma Kinase ALK Inhibitor Sales, Revenue and Gross Margin (2016-2021)
      • 12.1.4 Astellas Pharma Anaplastic Lymphoma Kinase ALK Inhibitor Products Offered
      • 12.1.5 Astellas Pharma Recent Development
    • 12.2 AstraZeneca
      • 12.2.1 AstraZeneca Corporation Information
      • 12.2.2 AstraZeneca Description and Business Overview
      • 12.2.3 AstraZeneca Anaplastic Lymphoma Kinase ALK Inhibitor Sales, Revenue and Gross Margin (2016-2021)
      • 12.2.4 AstraZeneca Anaplastic Lymphoma Kinase ALK Inhibitor Products Offered
      • 12.2.5 AstraZeneca Recent Development
    • 12.3 Betta Pharmaceuticals
      • 12.3.1 Betta Pharmaceuticals Corporation Information
      • 12.3.2 Betta Pharmaceuticals Description and Business Overview
      • 12.3.3 Betta Pharmaceuticals Anaplastic Lymphoma Kinase ALK Inhibitor Sales, Revenue and Gross Margin (2016-2021)
      • 12.3.4 Betta Pharmaceuticals Anaplastic Lymphoma Kinase ALK Inhibitor Products Offered
      • 12.3.5 Betta Pharmaceuticals Recent Development
    • 12.4 GlaxoSmithKline
      • 12.4.1 GlaxoSmithKline Corporation Information
      • 12.4.2 GlaxoSmithKline Description and Business Overview
      • 12.4.3 GlaxoSmithKline Anaplastic Lymphoma Kinase ALK Inhibitor Sales, Revenue and Gross Margin (2016-2021)
      • 12.4.4 GlaxoSmithKline Anaplastic Lymphoma Kinase ALK Inhibitor Products Offered
      • 12.4.5 GlaxoSmithKline Recent Development
    • 12.5 Merck
      • 12.5.1 Merck Corporation Information
      • 12.5.2 Merck Description and Business Overview
      • 12.5.3 Merck Anaplastic Lymphoma Kinase ALK Inhibitor Sales, Revenue and Gross Margin (2016-2021)
      • 12.5.4 Merck Anaplastic Lymphoma Kinase ALK Inhibitor Products Offered
      • 12.5.5 Merck Recent Development
    • 12.6 Novartis
      • 12.6.1 Novartis Corporation Information
      • 12.6.2 Novartis Description and Business Overview
      • 12.6.3 Novartis Anaplastic Lymphoma Kinase ALK Inhibitor Sales, Revenue and Gross Margin (2016-2021)
      • 12.6.4 Novartis Anaplastic Lymphoma Kinase ALK Inhibitor Products Offered
      • 12.6.5 Novartis Recent Development
    • 12.7 Pfizer
      • 12.7.1 Pfizer Corporation Information
      • 12.7.2 Pfizer Description and Business Overview
      • 12.7.3 Pfizer Anaplastic Lymphoma Kinase ALK Inhibitor Sales, Revenue and Gross Margin (2016-2021)
      • 12.7.4 Pfizer Anaplastic Lymphoma Kinase ALK Inhibitor Products Offered
      • 12.7.5 Pfizer Recent Development
    • 12.8 Roche
      • 12.8.1 Roche Corporation Information
      • 12.8.2 Roche Description and Business Overview
      • 12.8.3 Roche Anaplastic Lymphoma Kinase ALK Inhibitor Sales, Revenue and Gross Margin (2016-2021)
      • 12.8.4 Roche Anaplastic Lymphoma Kinase ALK Inhibitor Products Offered
      • 12.8.5 Roche Recent Development
    • 12.9 Takeda Pharmaceuticals
      • 12.9.1 Takeda Pharmaceuticals Corporation Information
      • 12.9.2 Takeda Pharmaceuticals Description and Business Overview
      • 12.9.3 Takeda Pharmaceuticals Anaplastic Lymphoma Kinase ALK Inhibitor Sales, Revenue and Gross Margin (2016-2021)
      • 12.9.4 Takeda Pharmaceuticals Anaplastic Lymphoma Kinase ALK Inhibitor Products Offered
      • 12.9.5 Takeda Pharmaceuticals Recent Development
    • 12.10 Turning Point Therapeutics
      • 12.10.1 Turning Point Therapeutics Corporation Information
      • 12.10.2 Turning Point Therapeutics Description and Business Overview
      • 12.10.3 Turning Point Therapeutics Anaplastic Lymphoma Kinase ALK Inhibitor Sales, Revenue and Gross Margin (2016-2021)
      • 12.10.4 Turning Point Therapeutics Anaplastic Lymphoma Kinase ALK Inhibitor Products Offered
      • 12.10.5 Turning Point Therapeutics Recent Development
    • 12.11 Astellas Pharma
      • 12.11.1 Astellas Pharma Corporation Information
      • 12.11.2 Astellas Pharma Description and Business Overview
      • 12.11.3 Astellas Pharma Anaplastic Lymphoma Kinase ALK Inhibitor Sales, Revenue and Gross Margin (2016-2021)
      • 12.11.4 Astellas Pharma Anaplastic Lymphoma Kinase ALK Inhibitor Products Offered
      • 12.11.5 Astellas Pharma Recent Development

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Anaplastic Lymphoma Kinase ALK Inhibitor Industry Trends
    • 13.2 Anaplastic Lymphoma Kinase ALK Inhibitor Market Drivers
    • 13.3 Anaplastic Lymphoma Kinase ALK Inhibitor Market Challenges
    • 13.4 Anaplastic Lymphoma Kinase ALK Inhibitor Market Restraints

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Anaplastic Lymphoma Kinase ALK Inhibitor Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      The characterization of anaplastic lymphoma kinase (ALK) gene and their role in the development and progression of ALK positive cancer has transformed the cancer therapeutics market. The extensive research activities by the researchers have led to the development of novel anaplastic lymphoma kinase inhibitors which belongs to the class of tyrosine receptor kinase and are used in the management of cancer.

      Market Analysis and Insights: Global and United States Anaplastic Lymphoma Kinase ALK Inhibitor Market
      This report focuses on global and United States Anaplastic Lymphoma Kinase ALK Inhibitor market.
      In 2020, the global Anaplastic Lymphoma Kinase ALK Inhibitor market size was US$ million and it is expected to reach US$ million by the end of 2027, with a CAGR of % during 2021-2027. In United States the Anaplastic Lymphoma Kinase ALK Inhibitor market size is expected to grow from US$ million in 2020 to US$ million by 2027, at a CAGR of % during the forecast period.

      Global Anaplastic Lymphoma Kinase ALK Inhibitor Scope and Market Size
      Anaplastic Lymphoma Kinase ALK Inhibitor market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Anaplastic Lymphoma Kinase ALK Inhibitor market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2016-2027.
      For United States market, this report focuses on the Anaplastic Lymphoma Kinase ALK Inhibitor market size by players, by Type, and by Application, for the period 2016-2027. The key players include the global and local players which play important roles in United States.

      Segment by Type
      First Generation ALK Inhibitor
      Second Generation ALK Inhibitor
      Third Generation ALK Inhibitor

      Segment by Application
      Hospital Pharmacy
      Retail Pharmacy
      Others

      By Region
      North America
      United States
      Canada
      Europe
      Germany
      France
      U.K.
      Italy
      Russia
      Asia-Pacific
      China
      Japan
      South Korea
      India
      Australia
      China Taiwan
      Indonesia
      Thailand
      Malaysia
      Latin America
      Mexico
      Brazil
      Argentina
      Colombia
      Middle East & Africa
      Turkey
      Saudi Arabia
      UAE

      By Company
      Astellas Pharma
      AstraZeneca
      Betta Pharmaceuticals
      GlaxoSmithKline
      Merck
      Novartis
      Pfizer
      Roche
      Takeda Pharmaceuticals
      Turning Point Therapeutics


      Summary:
      Get latest Market Research Reports on Anaplastic Lymphoma Kinase ALK Inhibitor. Industry analysis & Market Report on Anaplastic Lymphoma Kinase ALK Inhibitor is a syndicated market report, published as Global and United States Anaplastic Lymphoma Kinase ALK Inhibitor Market Insights, Forecast to 2027. It is complete Research Study and Industry Analysis of Anaplastic Lymphoma Kinase ALK Inhibitor market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

      Last updated on

      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $3,500.00
      $7,000.00
      2,551.50
      5,103.00
      2,982.00
      5,964.00
      388,150.00
      776,300.00
      258,300.00
      516,600.00
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report